About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Emphasis on Preventive, Holistic Therapies Offers Possibilities for Pharmacists
The passage of the Patient Protection and Affordable Care Act represents an opportunity to begin repairing parts of our health care system. For example, pharmacists might be able to expand their scope of practice and become more involved with patients and prescribers. However, several roadblocks, including a lack of funding and some ambiguous congressional language, must first be overcome.
Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder
As a first-line therapy for adults and children 6 to 12 years of age for ADHD, LDX is associated with a lower daily average use, less need for augmenting the dose, and better persistence with therapy compared with other long-acting drugs. Dr. Goodman reviews the drug’s history, benefits and risks, labeling for abuse potential, adverse events, and overall safety profile.
David W. Goodman, MD
Drugs discussed include carglumic acid tablets (Carbaglu) for children and adults with excessive ammonia levels; adapalene topical 0.1% lotion (Differin) for patients with acne vulgaris; and velaglucerase alfa for injection (VPRIV), an enzyme replacement therapy for pediatric and adult patients with type-1 Gaucher disease.
Marvin M. Goldenberg, PhD, RPh, MS
Topics include therapies for blood pressure and lipids in the ACCORD trial, betrixaban versus warfarin for atrial fibrillation, the use of low-osmolar contrast agents in invasive cardiac catheterization, early clopidogrel and eptifibatide for acute coronary syndromes, a new formulation of diazoxide choline for hypertriglyceridemia, and a rosuvastatin/ezetimibe combination for reducing lipid levels.
David B. Nash, MD, MBA, discusses the quality debate in health care: the U.S. excels in the high-tech arena, but we must find new ways to compensate physicians and provide better patient access to care.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains how to ensure the safe use of pen injectors by medical personnel and by patients at home.
Matthew Grissinger, RPh, FASCP
Stephen Barlas reviews two bills that would improve the safety of drug ingredients and prevent counterfeit drugs from entering the U.S.
P&T presents the latest FDA approvals, drug indications, recalls, and industry updates.
Milnacipran (Savella) for fibromyalgia is reviewed.
Clayton English, PharmD; Jose A. Rey, PharmD, BCPP; and Chabely Rufin, PharmD Candidate